Synthesis and antiviral evaluation of halogenated β-D- and -L- erythrofuranosylbenzimidazoles

Journal of Medicinal Chemistry

Volumn 43, Issue 12, 2000, Pages 2464-2472

  Gudmundsson, Kristjan S ^a,c   Tidwell, Jeffrey ^a,c   Lippa, Nicole ^c   Koszalka, George W ^a,c   van Draanen, Nanine ^a,c   Ptak, Roger G ^b,c   Drach, John C ^c   Townsend, Leroy B ^c  

^a GLAXOSMITHKLINE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO 5,6 DICHLORO 1 (BETA DEXTRO ERYTHROFURANOSYL)BENZIMIDAZOLE; 2,5,6 TRICHLORO 1(BETA DEXTRO ERYTHROFURANOSYL)BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; DNA HYBRIDIZATION; DRUG STRUCTURE; DRUG SYNTHESIS;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL DIVISION; CELL LINE; CYTOMEGALOVIRUS; DRUG RESISTANCE, MICROBIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRUS 1, HUMAN; HUMANS; INHIBITORY CONCENTRATION 50; NUCLEOSIDES; PLAQUE ASSAY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033948633     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990195p     Document Type: Article

References (47)

1. Alford, C. A.; Britt, W. J. Cytomegalovirus. In The Human Cytomegalovirus; Roizman, B., Whitley, R. J., Lopez, C., Eds.; Raven Press: New York, 1993; pp 227-255.
2. Wingard, J. R.; Piantadosi, S.; Burns, W. H.; Zahurak, M. L.; Santos, G. W.; Saral, R. Cytomegalovirus Infections in Bone Marrow Transplant Recipients Given Intensive Cytoreductive Therapy. Rev. Infect. Dis. 1990, 12, S793-S804.
3. McKenzie, R.; Travis, W. D.; Dolan, S. A.; Pittaluga, S.; Feuerstein, I. M.; Shelhamer, J.; Yarchoan, R.; Masur, H. The Causes of Death in Patients with Human Immunodeficiency Virus Infection: A Clinical and Pathological Study with Emphasis on the Role of Pulmonary Diseases. Medicine 1991, 70, 326-343.
4. Britt, W. J.; Pass, R. F.; Stagno, S.; Alford, C. A. Pediatric Cytomegalovirus Infection. Transplant. Proc. 1991, 23, 115-117.
5. (a) Faulds, D.; Heel, R. C. Ganciclovir: A Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Cytomegalovirus Infections. Drugs 1990, 39, 597-638.
6. (b) Crumpacker, C. S.; Ganciclovir. N. Engl. J. Med. 1996, 335, 721-729.
7. Chrisp, P.; Clissold, S. P. Foscarnet. A Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic use in Immunocompromised Patients with Cytomegalovirus Retinitis. Drugs 1991, 41, 104-129.
8. Lalezari, J. P.; Drew, W. L.; Glutzer, E.; James, C.; Miner, D.; Flaherty, J.; Fisher, P. E.; Cundy, K.; Hannigan, J.; Martin, J. C.; Jaffe, H. S. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (Cidofovir): Results of a Phase I/II Study of a Novel Antiviral Nucleotide Analogue. J. Infect. Dis. 1995, 171, 788-796.
9. Sorbera, L. A.; Rabasseda, X.; Castaner, J. Fomivirsen Sodium: Antiviral ISIS-2922 Vitravene. Drugs Future 1998, 23, 1168-1175.
10. Field, A. K.; Biron, K. K. "The end of Innocence" Revisited: Resistance to Antiviral Drugs. Clin. Microbiol. Rev. 1994, 7, 1-13.
11. (a) Townsend, L. B.; Revankar, G. R. Benzimidazole Nucleosides, Nucleotides, and Related Derivatives. Chem. Rev. 1970, 70, 389-438.
12. (b) Revankar, G. R.; Townsend, L. B. The Synthesis of 2-Chloro-1-(β-D-ribofuranosyl)benzimidazole and Certain Related Derivatives. J. Heterocycl. Chem. 1968, 5, 477-483.
13. (a) Devivar, R. V.; Drach J. C.; Townsend, L. B. Benzimidazole Ribonucleosides: Observation of an Unexpected Nitration when Performing Nonaqueous Diazotizations with tert-Butyl Nitrate. Bioorg. Med. Chem. Lett. 1992, 2, 1105-1110.
14. (b) Devivar, R. V.; Kawashima, E.; Revankar, G. R.; Breitenbach, J. M.; Kreske, E. D.; Drach, J. C.; Townsend, L. B. Benzimidazole Ribonucleosides: Design, Synthesis and Antiviral Activity of Certain 2-(Alkylthio)- and 2-(Benzylthio)-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 1994, 37, 2942-2949.
15. Townsend, L. B.; Devivar, R. V.; Turk, S. R.; Nassiri, M. R.; Drach, J. C. Design, Synthesis and Antiviral Activity of Certain 2,5,6-Trihalo-1-(β-D-ribofuranosyl)-benzimidazoles. J. Med. Chem. 1995, 38, 4098-4105.
16. (a) Drach, J. C.; Townsend, L. B.; Nassiri, M. R.; Turk, S. R.; Coleman, L. A.; Devivar, R. V.; Genzlinger, G.; Kreske, E. D.; Renau, T. E.; Westerman, A. C.; Shipman, C., Jr.; Biron, K, K.; Dornsife, R.; Kern, E. R. Benzimidazole Ribonucleosides: A New Class of Antivirals with Potent and Selective Activity Against Human Cytomegalovirus. Fifth International Conference on Antiviral Research, Vancouver, British Columbia, Canada, March 1992.
17. (b) Turk, S. R.; Black, J. M.; Borysko, K. Z.; Edwards, C. A.; Nassiri, M. R.; Townsend, L. B.; Drach, J. C. Benzimidazole Ribonucleosides: Mode of Action of TCRB in HCMV-Infected Cells. Fifth International Conference on Antiviral Research, Vancouver, British Columbia, Canada, March 1992.
18. Underwood, M. R.; Harvey, R. J.; Stanat, S. C.; Hemphilll, M. L.; Miller, T.; Drach, J. C.; Townsend, L. B.; Biron, K. K. Inhibition of Human Cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 1998, 72, 717-725.
19. (a) Koszalka, G. W.; Chamberlain, S. D.; Harvey, R. J.; Frick, L. W.; Good, S. S.; Davis, M. L.; Smith, A.; Drach, J. C.; Townsend, L. B.; Biron, K. K. Benzimidazoles for the Treatment of Human Cytomegalovirus. Antiviral Res. 1996, 30, A43.
20. (b) Chamberlain, S. D.; Chan, J. H.; Tidwell, J. H.; Peckham, G. E.; Harvery, R. J.; Dornsife R. E.; Frick, L. W.; Townsend, L. B.; Drach, J. C.; Koszalka, G. W. Synthesis and Evaluation of a Series of Carbohydrate Modified Derivatives of the Anti-HCMV Agent, 5,6-Dichloro-2-isopropylamino-1-(β-L-ribofuranosyl)benzimidazole (1263W94). 214th ACS National Meeting, San Fransisco, CA, April 1997.
21. Drew, W. L.; Lalezari, J. P.; Wang, L. H.; Miner, R. C.; Aberg, J. A.; Wire, M. B.; Jacobson, M. A. In Vivo Anti-CMV Activity and Safety of Oral 1263W94 in HIV-Infected Subjects with Asymptomatic CMV Shedding. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998.
22. (a) Saluja, S.; Zou, R.; Drach, J. C.; Townsend, L. B. Structure-Activity Relationships Among 2-Substituted 5,6-Dichloro-, 4,6-Dichloro-, and 4,5-Dichloro-1-[(2-hydroxyethoxy)methyl)- and 1-[(1,3-dihydroxy-2-propoxy)methyl]-benzimidazoles. J. Med. Chem. 1996, 39, 881-891.
23. (b) Migawa, M. T.; Girardet, J.-L.; Walker, J. A. II; Koszalka, G. W.; Chamberlain, S. D.; Drach, J. C.; Townsend, L. B. Design, Synthesis and Antiviral Activity of α-Nucleosides: D- and L-Isomers of Lyxofuranosyl- and (5-Deoxylyxofuranosyl)benzimidazoles. J. Med. Chem. 1998, 41, 1242-1251.
24. Girardet, J.-L.; Drach, J. C.; Chamberlain, S. D.; Koszalka, G. W.; Townsend, L. B. Design, Synthesis and Antiviral Activity of α-L-Arabinofuranosyl Derivatives of 2-Substituted-5,6-dichlorobenzimidazoles. Nucleosides Nucleotides 1998, 17, 2389-2401.
25. Drach, J. C.; Bush, P. M.; Ptak, R. G.; Devivar, R. V.; Townsend, L. B.; Davis, M. G.; Underwood, M. R.; Biron, K. K. Halogenated Benzimidazole 5′-Deoxyribonucleosides are Potent and Selective Inhibitors of Human Cytomegalovirus Replication. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995.
26. (a) Gudmundsson, K. S.; Drach, J. C.; Townsend, L. B. Synthesis and Antiviral Evaluation of Several 5′-Derivatives of 2,5,6-Trichloro-1-(β-D-ribofuranosyl)benzimidazole (TCRB). ACS National Meeting, Chicago, IL, August 1995.
27. (b) Gudmundsson, K. S.; Drach, J. C.; Wotring, L.; Townsend, L. B. Synthesis and Antiviral Activity of Certain 5′-Modified Analogues of 2,5,6-Trichloro-1-(β-D-ribofuranosyl)benzimidazole. J. Med. Chem. 1997, 40, 785-793.
28. (a) Shah, R. H. Synthesis of Sugars From D-Ribonolactone II. An Alternative Synthesis of D-Erythrose. J. Carbohydr. Chem. 1986, 5, 139-146.
29. (b) Baggett, N.; Buchanan, J. G.; Fatah, M. Y.; Lachut, C. H.; McCullough, K. J.; Webber, J. M. Benzylidene Acetals of the D-Ribonolactones: A Structural Reassessment. J. Chem. Soc., Chem. Commun. 1985, 1826-1827.
30. Andersson, R.; Theander, O.; Westerlund, E. Studies on D-Erythrose and its Acetates. Carbohydr. Res. 1978, 61, 501-509.
31. Kawashima, E.; Gupta, P. K.; Devivar, R. V.; Townsend, L. B. 2,5,6-Trichlorobenzimidazole. In Improved and New Synthetic Procedures, Methods, and Techniques; Townsend, L. B., Tipson, R. S., Eds.; Wiley-Interscience: New York, 1991; p 21.
32. Baker, B. R. In The Ciba Foundation Symposium on the Chemistry and Biology of the Purines; Wolstenholme, G. E. W., O'Connors, C. M., Eds.; Churchill: London, 1957; p 120.
33. Omar, A. M. E.; Habib, N. S.; Aboulwafa, O. M. The Cyclodesulfurization of Thio Compounds: XVI. Dicyclohexylcarbodiimide as an Efficient Cyclodesulfurizing Agent in the Synthesis of Heterocyclic Compounds from Various Thio Compounds. Synthesis 1977, 864-865.
34. Synthesized from β-L-erythrofuranose as described in the Experimental Section.
35. Krosky, P. M.; Underwood, M. R.; Turk, S. R., Feng, K. W.-H.; Jain, R. K.; Ptak, R. G.; Westerman, A. C.; Biron, K. K.; Townsend, L. B.; Drach, J. C. Resistance of Human Cytomegalovirus to Benzimidazole Ribonucleosides Maps to Two Open Reading Frames: UL89 and UL56. J. Virol. 1998, 72, 4721-4728.
36. Talarico, C. L.; Davis, M. G.; Sethna, P. B.; Miller, W. H.; Underwood, M. R.; Baldanti, F.; Biron, K. K.; Harvey, R. J. Antiviral activity of the benzimidazole 1263W94 is mediated through the protein kinase activity of the HCMV UL97. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 1998.
37. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Techniques for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.
38. Hudlicky, T.; Luna, H.; Price, J. D.; Rulin, F. Microbial Oxidation of Chloroaromatics in the Enantiodivergent Synthesis of Pyrrolizidine Alkaloids: Trihydroxyheliotridanes. J. Org. Chem. 1990, 55, 4683-4687.
39. Tidwell, J. H.; Chamberlain, S. D.; Hammitt, R.; Burns, C. L.; Koszalka, G. W. An Efficient and Scalable Synthesis of the AntiHCMV Agent 1263W94 (ORGN-172). 216th ACS National Meeting, Boston, MA, August 1998.
40. Turk, S. R.; Shipman, C., Jr.; Nassiri, R.; Genzingler, G.; Krawczyk, S. H.; Townsend, L. B.; Drach, J. C. Pyrrolo[2,3-d]-pyrimidine Nucleosides as Inhibitors of Human Cytomegalo-virus. Antimicrob. Agents Chemother. 1987, 31, 544-550.
41. Prichard, M. N.; Turk, S. R.; Coleman, L. A.; Engelhardt, S. L.; Shipman, C., Jr.; Drach, J. C. A Microtiter Virus Yield Reduction Assay for the Evaluation of Antiviral Compounds Against Human Cytomegalovirus and Herpes Simplex Virus. J. Virol. Methods 1990, 28, 101-106.
42. See ref 14. This reference describes a single-cycle DNA hybridization assay with multiplicity of infection (moi) of 1.5-2. In the current study, a multicycle assay with a lower moi of approximately 0.013 was used and adapted to a 96-well format.
43. Prichard, M. N.; Shipman, C., Jr. A Three-Dimensional Model to Analyze Drug-Drug Interactions. Antiviral Res. 1990, 14, 181-206.
44. Prichard, M. N.; Prichard, L. E., Baguley, W. A.; Nassiri, M. R.; Shipman, C., Jr. Three-Dimensional Analysis of the Synergistic Cytotoxicity of Ganciclovir and Zidovudine. Antimicrob. Agents Chemother. 1991, 35, 1060-1065.
45. (a) Averett, D. R. Anti-HIV Compound Assessment by Two Novel High-capacity Assays. J. Virol. Methods 1989, 23, 263-276.
46. (b) Prus, K. L.; Averett, D. R.; Zimmerman, T. P. Transport and Metabolism of 9-β-D-Arabinofuranosylguanine in a Human T-lymphoblastoid Cell Line: Nitrobenzylthioinosine-sensitive and Insensitive Influx. Cancer Res. 1990, 50, 1817-1821.
47. (c) Dornsife, R. E.; St. Clair, M. H.; Huang, A. T.; Panella, T. J.; Koszalka, G. W.; Burns, C. L.; Averett, D. R. Anti Human Immunodeficiency Virus Synergism by Zidovudine (3′-Azidothymidine) and Didanosine (Dideoxyinosine) Contrasts with their Additive Inhibition of Normal Human Marrow Progenitor Cells. Antimicrob. Agents Chemother. 1991, 35, 322-328 and references cited in these publications.